On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...